Related Experiment Videos
[Therapy of paroxysmal hypokalemic paralysis: experience with diclofenamid]
1Kinderklinik, Stadtklinik Baden-Baden.
Insights
Familial hypokalemic periodic paralysis in a boy was initially managed with acetazolamide and potassium. Diclofenamide therapy later effectively suppressed frequent paralysis attacks and muscle weakness.
Area of Science:
- Neurology
- Genetics
- Endocrinology
Background:
- Familial hypokalemic periodic paralysis (HypoPP) is a rare genetic disorder.
- Characterized by recurrent episodes of muscle weakness and paralysis.
- Typically triggered by factors affecting potassium levels.
Abstract:
A case of familial hypokalemic periodic paralysis is discussed in a boy whose first paralysis occurred at 11 years of age. At first the paralysis was controlled by acetazolamid and potassium therapy. Later, frequent attacks of paralysis and muscle weakness developed necessitating a change of therapy. Diclofenamid has now already been administered for 2 years. It is well tolerated and has suppressed further attacks.